Yin Ye joined Beijing BGI Biotechnology Co., Ltd., a branch of BGI, in 2002, and has been engaged in in vitro diagnostic reagent research and development, product registration, production management, quality management, and marketing. He has rich experience in biological product research and development, production, quality control, registration and clinical application promotion of biotechnology. He has presided over the application of multiple patents and dozens of in vitro diagnostic reagents. He has a deep understanding of GMP/IVD/ISO series quality management systems. . In the spring of 2003, Yin Ye was one of the main participants in scientific research on the early diagnosis of "atypical pneumonia". After BGI efficiently completed the SARS virus sequencing and obtained the diagnostic protein, he led the team to complete the SARS diagnostic reagent within 24 hours. All R&D and application materials were prepared and successfully obtained approval from the State Pharmacy Administration. Subsequently, BGI promptly sent 300,000 "immune detection kits" free of charge to the front line of SARS prevention and treatment.
In 2009, due to his outstanding overall performance, Yin Ye was transferred to the headquarters of BGI and was responsible for the global industrial promotion of genomics and bioinformatics. He also served as president of BGI Technology Cooperation Division, Head of global production platform, assistant dean of BGI Research Institute, chief operating officer of BGI Group, executive president of BGI Medicine, etc. He was responsible for establishing BGI’s global marketing team, building BGI’s global scientific research and industrial platform, and completing BGI’s global layout. During this period, Yin Ye successively served as the general commander of the global "Thousand Animal and Plant Genomes Project", the first person in charge of the "Million Human Re-sequencing Project", the general person in charge of the "Mongolian Plateau Characteristic Species Genome Project", and the "Mongolian Genome Project" project Hosts, etc., have chaired or participated in hundreds of international genome cooperation projects, published many papers in top international academic journals such as Nature, and promoted the establishment of good cooperative relations between BGI and global biological research institutions to promote genomics research and molecular breeding. It has made important contributions to the development of scientific research in the fields of medical care, health, environment and energy, and to providing the general public with cutting-edge biotechnology application services in the fields of medical care, agriculture, environment and energy. During his tenure as CEO of BGI, he fully implemented the "4P medicine" concept of individualization, prediction, intervention, and participation, and promoted the development of clinical applications of genetic testing to reduce the harm of birth defects and major diseases to human health.
BGI successfully completed the wholly-owned acquisition of Complete Genomics, a US listed company, in 2013. Yin Ye played a key role as a core member in BGI’s overseas acquisition process and accumulated abundant capital. Operational and financing investment experience.
Currently, Yin Ye serves as the Executive President of BGI Co., Ltd., leading the team to actively promote the industrial application of cutting-edge biotechnology and genomics research results, and provide them to the world's top medical institutions, scientific research institutions, universities, Pharmaceutical companies, breeding companies, etc. provide complete genomics solutions, provide diagnosis, intervention and treatment basis for clinical behavior, provide technology and research services for life sciences and medical innovation, and are committed to becoming a global leader in the gene technology application service industry.
Won the Top Ten Economic Trends Figures Award in China in 2014
Won the Dalian University of Technology's "2014 Alumni of the Year" Young Alumni Achievement Award in 2015